Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data from a Local Registry

Arthritis Care and Research

Volumn 68, Issue 4, 2016, Pages 432-439

  Favalli, Ennio Giulio ^a   Pregnolato, Francesca ^b   Biggioggero, Martina ^c   Becciolini, Andrea ^a   Penatti, Alessandra Emiliana ^c   Marchesoni, Antonio ^a   Meroni, Pier Luigi ^c  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; HAZARD RATIO; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PROPENSITY SCORE; REGISTER; RHEUMATOID ARTHRITIS; SURVIVAL RATE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG ADMINISTRATION; IMMUNOLOGY; ITALY; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT FAILURE;

ADALIMUMAB; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETANERCEPT; FEMALE; HUMANS; INFLIXIMAB; ITALY; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84961880621     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22788     Document Type: Article

References (29)

1. Lipsky PE, van der Heijde DM, St.Clair EW, Furst DE, Breedveld FC, Kalden JR, et al., Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
2. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al., Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
3. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al., Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
4. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al., The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2005; 54: 26-37.
5. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al., Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-82.
6. St.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al., Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43.
7. Wolfe F., Why results of clinical trials and observational studies of anti-tumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis 2004; 63 Suppl 2: ii13-7.
8. Caporali R, Pallavicini FB, Filippini M, Gorla R, Marchesoni A, Favalli EG, et al., Treatment of rheumatoid arthritis with anti-TNF-α agents: a reappraisal. Autoimmun Rev 2009; 8: 274-80.
9. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, et al., TNF-α antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009; 1173: 837-46.
10. Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, et al., Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 2015; 74: 354-60.
11. Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, et al., Long-term retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 2012; 39: 1179-84.
12. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, et al., A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012; 71: 1134-42.
13. Kobayakawa T, Kojima T, Takahashi N, Hayashi M, Yabe Y, Kaneko A, et al., Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate. Mod Rheumatol 2015; 25: 251-6.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
15. Austin PC, Platt RW., Survivor treatment bias, treatment selection bias, and propensity scores in observational research. J Clin Epidemiol 2010; 63: 136-8.
16. R Core Team. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2012.
17. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL, for the British Society for Rheumatology Biologics Register. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 583-9.
18. Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H, et al., Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011; 50: 196-203.
19. Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo RM, et al., Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. Joint Bone Spine 2014; 81: 352-9.
20. Yazici Y, Krasnokutsky S, Barnes JP, Hines PL, Wang J, Rosenblatt L., Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 2009; 36: 907-13.
21. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al., Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
22. Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, et al., TNFα antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007; 74: 148-54.
23. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, for the Swiss Clinical Quality Management Physicians. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009; 61: 560-8.
24. Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, et al., Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival. Semin Arthritis Rheum 2013; 43: 447-57.
25. Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, et al., Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol 2011; 38: 1273-81.
26. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al., Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010; 69: 817-21.
27. Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G., Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 2012; 64: 3850-5.
28. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C., Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013; 72: 165-78.
29. Kristensen LE, Saxne T, Nilsson JA, Geborek P., Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis: results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006; 8: R174.